Read More

SELLAS Life Sciences Reports Follow-Up Immune Response And Survival Data In Completed Phase 1 Study Of Galinpepimut-S Combined With Opdivo In Advanced Malignant Pleural Mesothelioma; Primary Endpoint Of Safety And Efficacy Met

- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median Overall Survival in

SLS

Read More

Codexis Announces Purchase Agreement With Nestlé Health Science For CDX-7108; Under The Terms, Codexis Will Receive Up To $45M In Potential Milestone Payments, Including A $5M Upfront Payment, As Well As Single-Digit Net-Sales-Based Royalties

Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science,

CDXS

Read More

Hoth Therapeutics Announces Expansion Of FDA Cleared First-In-Human Clinical Trial For Cancer Patients Of HT-001 At University Of Miami For The Treatment Of Skin Toxicities Associated With EGFRi Treatments

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received approval from the University of Miami to enroll patients for its first in human clinical

HOTH

Read More

Cytokinetics To Host Investor Call On December 27 To Discuss The Topline Results From SEQUOIA-HCM, The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of its senior management will host an investor call at 8:30 AM Eastern Time on Wednesday, December 27, 2023 to discuss the topline results from

CYTK

Read More

Scilex Announces Filing Of A New Drug Submission To Health Canada’s Pharmaceutical Drugs Directorate, Bureau Of Cardiology, Allergy And Neurological Sciences For The Approval Of ELYXYB For Acute Treatment Of Migraine With Or Without Aura In Canada

ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size is

SCLX